Will BAX's Q1 Earnings Improve Following Transformation Completion?

Core Viewpoint - Baxter International Inc. is expected to report first-quarter 2025 results on May 1, with a consensus estimate for revenues at $2.57 billion, reflecting a 28.4% decline year-over-year, and earnings per share (EPS) estimated at 48 cents, indicating a 26.2% year-over-year decline [1][2]. Revenue Estimates - The consensus estimate for total revenues is $2.57 billion, which represents a significant decline of 28.4% from the prior-year quarter [1]. - The model estimates total revenues from continuing operations to improve by 3.8% at constant currency to $2.58 billion [2]. Growth Factors - Baxter is likely to report moderate growth due to strong momentum in certain product lines, aided by easing macroeconomic pressures, with sales from continuing operations improving by 2% at constant currency in Q4 2024 [3]. - The company anticipates sales growth from continuing operations to be in the range of 3-4% [3]. Margin and Cost Considerations - Margins declined in the last reported quarter primarily due to one-time costs, including goodwill impairment charges and business optimization costs, which are expected to be reduced in the first quarter, potentially boosting the bottom line [4]. - The completion of a transformational plan, including the spin-off of certain business segments, is expected to enhance operational efficiency and improve EPS to a range of 47-50 cents [5]. Impact of Hurricane Helene - Baxter's recovery from Hurricane Helene has ensured minimal disruption in 2025, with all manufacturing lines restored to pre-hurricane levels, securing supply continuity [6]. - The Medical Products & Therapies segment is expected to have recovered from the hurricane's impact, aiding sales during the first quarter [7]. Segment Performance - Strong growth in infusion therapies, particularly the Novum IQ pump platform, is expected to continue, contributing positively to sales [8]. - The growth of parenteral nutrition products and Advanced Surgery products, along with recovery in IV solutions sales, is anticipated to drive segmental sales up by 6.6% at constant currency to $1.28 billion [9]. - The Healthcare Systems & Technologies segment may face challenges due to softness in the U.S. primary care market and delays in international capital spending, but patient support systems are expected to show resilience [10]. - The Pharmaceuticals segment is likely to improve, driven by a rebound in injectable drug sales and strong demand in drug compounding, with estimated sales growth of 14.4% at constant currency to $280.4 million [12][13].